M&A Deal Summary

Watson Pharmaceuticals Acquires Pharmaco Hf.

On October 31, 2012, Watson Pharmaceuticals acquired medical products company Pharmaco Hf. for 4.3B EUR

Acquisition Highlights
  • This is Watson Pharmaceuticals’ 3rd transaction in the Medical Products sector.
  • This is Watson Pharmaceuticals’ 0th largest (disclosed) transaction.
  • This is Watson Pharmaceuticals’ 1st transaction in Iceland.

M&A Deal Summary
Date 2012-10-31
Target Pharmaco Hf.
Sector Medical Products
Buyer(s) Watson Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 4.3B EUR

Target

Pharmaco Hf.

Hafnarfirdi,, Iceland
website
Pharmaco Hf. engages in the development, manufacture, and sale of generic pharmaceuticals.

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Watson Pharmaceuticals

Florham Park, New Jersey, United States

website

Category Company
Founded 1931
Sector Medical Products
Employees1,325
DESCRIPTION

Watson Pharmaceuticals, Inc.,is a specialty pharmaceutical company that develops, manufactures, markets and distributes branded and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

DEAL STATS #
Overall 8 of 9
Sector (Medical Products) 3 of 4
Type (Add-on Acquisition) 4 of 5
Country (Iceland) 1 of 1
Year (2012) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-01-24 Ascent Pharmahealth

Melbourne, Australia

Ascent Pharmahealth Ltd, markets in Australia, Singapore, Malaysia, Hong Kong, Vietnam, Thailand and other Asian countries with a range of generic pharmaceuticals, consumer skincare and over the-counter (OTC) medicines. Ascent has a regional manufacturing facility located in Singapore which manufactures prescription and OTC products in varied dosage forms for the Southeast Asia market.

Buy AU$375M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-01-23 Uteron Pharma SA

Grâce-Hollogne, Belgium

Uteron Pharma SA is a development-based company dedicated to female healthcare. Uteron has a diversified portfolio of innovative products in different stages of development. The product development portfolio includes a hormonal IUD, a next generation oral contraceptives containing natural estrogen, a new generation of biochemical tests that will significantly increase in-vitro fertilization success rates, and pharmacologic treatments for cervical dysplasia.

Buy $150M
Mergr

Product

Company

Legal